Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.84 EUR
Change Today -0.02 / -0.70%
Volume 171.6K
THR On Other Exchanges
Symbol
Exchange
EN Brussels
Berlin
As of 11:35 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Patrik De Haes ViBio, BVBA

Chief Executive Officer and Executive Director,ThromboGenics NV
AgeTotal Calculated CompensationThis person is connected to 8 board members in 1 different organizations across 1 different industries.

See Board Relationships
--€711,000
As of Fiscal Year 2014

Background*

Dr. Patrik De Haes, ViBio, BVBA, M.D. has been the Chief Executive Officer of ThromboGenics NV since September 01, 2008. Dr. De Haes served as the Chief Operating Officer of ThromboGenics NV until September 1, 2008. Previously, he served as Head of the Global Insulin Infusion business at Roche in Switzerland. He served as President and Chief Executive Officer of Disetronic Medical Systems Inc., a leading company in insulin infusion therapy, in Minneapolis, USA. At Sandoz ...

Read Full Background

Corporate Headquarters*

Gaston Geenslaan 1
Leuven, Flemish Brabant 3001

Belgium

Phone: 32 1 675 13 10
Fax: 32 1 675 13 11

Board Members Memberships*

Chief Executive Officer and Executive Director

Education*

Bachelor's Degree
Katholieke Universiteit Leuven

Other Affiliations*

Annual Compensation*

Salary€605,000
Bonus€85,000
Total Annual Compensation€690,000

Stock Options*

All Other Compensation€21,000

Total Compensation*

Total Annual Cash Compensation€711,000
Total Short Term Compensation€690,000
Other Long Term Compensation€21,000
Total Calculated Compensation€711,000
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THR:BB €2.84 EUR -0.02

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.